We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Kidney Disease Biomarker May Indicate Lung Problems

By LabMedica International staff writers
Posted on 09 Oct 2018
Print article
Image: An albumin immunoturbidimetric assay urine or serum plasma; standard microalbumin range is 0.4-500mg/L (Photo courtesy of Sentinel Diagnostics).
Image: An albumin immunoturbidimetric assay urine or serum plasma; standard microalbumin range is 0.4-500mg/L (Photo courtesy of Sentinel Diagnostics).
Chronic lower respiratory diseases (CLRD) are the fourth leading cause-of-death and a major source of health care costs. CLRD includes chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, and asthma, airflow limitation as a physiologic correlate, and acute exacerbations as the major clinical manifestation.

Albuminuria is a commonly used biomarker of endothelial damage in the kidneys and correlates with microvascular dysfunction throughout the body, including in the pulmonary circulation. Cross-sectional studies suggest albuminuria is increased in COPD patients, among whom it is adversely associated with lung function, gas exchange, and hypoxia.

A large team of scientists working with the Columbia University College of Physicians & Surgeons (New York, NY, USA) conducted their study by pooling information from 31,877 participants (average age: 60 years) from six cohort studies. Urine albumin was measured by nephelometry or immunoturbidometry, and urine creatinine assessed by the Jaffe method. These were used to calculate the spot urine albumin-to-creatinine ratio, called “albuminuria.” Pre-bronchodilator lung function was measured using water-seal, dry-rolling-seal, or flow sensing spirometers. Incident moderate-to-severe COPD was defined as FEV1/FVC<LLN and FEV1<80% at the final spirometry exam.

The team reported that they found for each standard deviation increase in albuminuria, there was a 15% increase in those who developed moderate-to-severe COPD; a 26% increase in COPD hospitalizations and deaths; and 3% greater decline in FEV1 (the amount of air that can be forcibly exhaled in one second) and an 11% greater decline in the ratio between FEV1 and FVC (the total amount of air that can be forcibly exhaled after taking the deepest breath possible). Both FEV1 and FEV1/FVC are important measures of lung function.

Elizabeth C. Oelsner, MD, MPH, an Assistant Professor of Medicine and lead author of the study, said, “Our study helps to explain why COPD patients often have a constellation of vascular problems, including heart and kidney disease. This makes it all the more important for clinicians to encourage avoidance of exposures like smoking and treatment of diseases like hypertension and diabetes that cause endothelial dysfunction.” The study was published on September 28, 2018, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:
Columbia University College of Physicians & Surgeons

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more